| Literature DB >> 25134772 |
Yinghua Jin1, Ping Qi1, Zhiwei Wang2, Qirong Shen2, Jian Wang2, Weige Zhang3, Hongrui Song4.
Abstract
Combretastatin A-4 (CA-4), its analogues and their excellent antitumoral and antivascular activities, have attracted considerable interest of medicinal chemists. In this article, a docking simulation was used to identify molecules having the same binding mode as the lead compound, and 3D-QSAR models had been built by using CoMFA based on docking. As a result, these studies indicated that the QSAR models were statistically significant with high predictabilities (CoMFA model, q2 = 0.786, r2 = 0.988). Our models may offer help to better comprehend the structure-activity relationships for this class of compounds and also facilitate the design of novel inhibitors with good chemical diversity.Entities:
Mesh:
Substances:
Year: 2011 PMID: 25134772 PMCID: PMC6264539 DOI: 10.3390/molecules16086684
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Combretastatin A-4 and its water-soluble sodium phosphate prodrug CA-4P.
Figure 2Binding conformations of the docked colchicine (purple) and crystal colchicines (green) at the active site of tubulin.
Structures having the same binding modes as CA-4 and used in the training and test set.
| Compounds | Ar1 | X1 | X2 | Ar2 | Literature |
|---|---|---|---|---|---|
| 1 | CH | CH | [ | ||
| 2 | CO | CO | [ | ||
| 3 | CH2 | NH | [ | ||
| 4 | CH | CH | [ | ||
| 5 | CH | CH | [ | ||
| 6 | CH2 | NCH3 | [ | ||
| 7 | CH2 | NCH2CH3 | [ | ||
| 8 | CH | CH | [ | ||
| 9 | CH | CH | [ | ||
| 10 | CF | CH | [ | ||
| 11 | CF | CF | [ | ||
| 12 | CF | CH | [ | ||
| 13 | CH2 | CH2 | [ | ||
| 14 | CH | CH | [ | ||
| 15 | CH | CH | [ | ||
| 16 | CH | CH | [ | ||
| 17 | CH | CH | [ | ||
| 18 | CH | CH | [ | ||
| 19 | CCN | CH | [ | ||
| 20 | CH | CCN | [ | ||
| 21 | CCN | CH | [ | ||
| 22 | CH | CH | [ | ||
| 23 | CH | CH | [ | ||
| 24 | CH | CH | [ | ||
| 25 | [ | ||||
| 26 | CH | CH | [ | ||
| 27 | CH | CH | [ | ||
| 28 | [ | ||||
| 29 | CH | CH | [ | ||
| 30 | CHCN | CH2 | [ | ||
| 31 | [ | ||||
| 32 | [ | ||||
| 33 | [ | ||||
| 34 | [ | ||||
| 35 | CH | CH | [ | ||
| 36 | CH | CH | [ | ||
| 37 | CH | CH | [ | ||
| 38 | CH | CH | [ | ||
| 39 | CH | CH | [ | ||
| 40 | CH | CH | [ | ||
| 41 | CH | CH | [ | ||
| 42 | CH | CH | [ | ||
| 43 | CH | CH | [ | ||
| 44 | [ | ||||
| 45 | CH | CH | [ | ||
Relative activities, predicted activities and docking results for all studied compounds.
| Compound | Relative | Predicted | Residue | MolDockScore |
|---|---|---|---|---|
| 1 | 0.00 | 0.03 | −0.03 | −92.11 |
| 2 t | −0.18 | −0.08 | −0.10 | −102.1 |
| 3 | −1.18 | −1.20 | 0.01 | −83.85 |
| 4 | −0.67 | −0.68 | 0.01 | −86.39 |
| 5 | −0.26 | −0.26 | −0.01 | −84.69 |
| 6 | −1.06 | −1.02 | −0.04 | −81.16 |
| 7 | −0.59 | −0.56 | −0.02 | −95.79 |
| 8 | 0.23 | 0.18 | 0.05 | −84.34 |
| 9 | −0.02 | −0.03 | 0.01 | −80.87 |
| 10 | −0.05 | −0.02 | −0.03 | −117.5 |
| 11 | −0.17 | −0.13 | −0.04 | −105.8 |
| 12 | 0.29 | 0.21 | 0.08 | −103.8 |
| 13 t | −0.26 | −0.21 | −0.05 | −88.41 |
| 14 t | -0.26 | −0.06 | −0.19 | −90.39 |
| 15 | 0.08 | 0.10 | −0.01 | −85.25 |
| 16 t | 0.05 | −0.12 | 0.17 | −82.73 |
| 17 t | 0.08 | −0.07 | 0.15 | −81.14 |
| 18 | −0.10 | −0.09 | 0.00 | −94.13 |
| 19 | −0.40 | −0.43 | 0.04 | −101.3 |
| 20 t | −0.10 | −0.07 | −0.03 | −108.7 |
| 21 t | −0.18 | −0.44 | 0.27 | −101.9 |
| 22 | 0.00 | 0.00 | 0.00 | −80.97 |
| 23 | −0.18 | −0.15 | −0.03 | −84.11 |
| 24 t | −0.18 | −0.08 | −0.09 | −95.84 |
| 25 | −0.23 | −0.21 | −0.03 | −123.1 |
| 26 t | −0.06 | −0.24 | 0.18 | −101.0 |
| 27 | −0.48 | −0.49 | 0.01 | −105.3 |
| 28 | −0.74 | −0.79 | 0.05 | −117.5 |
| 29 | −0.78 | −0.80 | 0.02 | −110.2 |
| 30 | −0.74 | −0.74 | 0.00 | −80.49 |
| 31 | 0.24 | 0.20 | 0.05 | −120.4 |
| 32 t | −0.37 | −0.59 | 0.23 | −126.9 |
| 33 | 0.18 | 0.20 | −0.02 | −125.1 |
| 34 | 0.11 | 0.16 | −0.04 | −118.4 |
| 35 | −1.16 | −1.15 | −0.01 | −89.72 |
| 36 | −0.14 | −0.14 | 0.00 | −83.71 |
| 37 | 0.17 | 0.19 | −0.01 | −95.28 |
| 38 | −0.92 | −0.95 | 0.03 | −88.45 |
| 39 | 0.04 | 0.01 | 0.03 | −89.74 |
| 40 | −0.73 | −0.72 | −0.01 | −113.6 |
| 41 | −1.22 | −1.21 | −0.01 | −130.7 |
| 42 t | −0.80 | −1.15 | 0.35 | −117.9 |
| 43 | 0.00 | 0.04 | −0.04 | −90.15 |
| 44 | 0.20 | 0.20 | 0.00 | −118.4 |
| 45 | −0.32 | −0.33 | 0.00 | −91.68 |
t Test set.
Figure 3Alignment of all the studied compounds.
Figure 4Interactions between the amino acids at colchicine-binding site and the most potent compound 13.
Figure 5Plot of relative and predicted activities for the training and test set compounds based on the CoMFA model.
Summary of the statistical parameters obtained from the CoMFA and analysis.
| Statistical parameters CoMFA | CoMFA |
|---|---|
| the number of training set compounds | 34 |
| Components | 5 |
| q2 | 0.786 |
| Convention r2 | 0.988 |
| Standard error of estimated | 0.055 |
| F values | 472.301 |
| Predictive r2 | 0.7412 |
| Fraction | |
| Steric | 79.7% |
| Electrostatic | 20.3% |
Figure 6CoMFA STDEV*COEFF contour maps based on compound 12. Green contours emphasize areas that bulky groups are favorable, while yellow contours highlight regions that bulky substituents are unfavorable.Blue contours represent areas where electropositive substituents in these positions will enhance the inhibitory ability on tubulin polymerization while red contours emphasize regions where electronegative groups will increase the inhibitory activity.
Figure 7CoMFA STDEV*COEFF contour maps based on compound 33 and CA-4 (1).